What Revna Biosciences does

Revna Biosciences (RevnaBio) is a precision medicine laboratory company founded in 2017 and domiciled in Delaware, USA with operational headquarters in Accra, Ghana. The company operates Africa's first and only triple A2LA ISO-accredited facility, holding ISO 15189:2022 for medical and clinical laboratories, ISO 20387:2018 for biobanking, and ISO/IEC 17043:2023 for testing and calibration laboratories — a combination that places its results within the ILAC MRA framework accepted by regulatory authorities in over 70 countries including the US FDA, European EMA, and the WHO. RevnaBio serves four named customer segments: individual patients seeking advanced diagnostics, healthcare providers requiring ISO-certified medical laboratory services, medical researchers conducting population genetics and pharmacogenomics studies, and life sciences and pharmaceutical sponsors needing central lab and clinical trial support in Africa. The company is co-founded and led by CEO Dr. Derrick Edem Akpalu, with Dr. Sylvia Anie as Board Chair, and operates a US regional office in Horsham, Pennsylvania to support global enterprise sales.

RevnaBio's service portfolio spans clinical diagnostics (haematology, clinical biochemistry, immunology, microbiology, serology, and advanced molecular diagnostics), comprehensive genomic and genetic testing (whole genome sequencing, whole exome sequencing, targeted gene panels, EGFR testing, carrier screening), pharmacogenetic and pharmacogenomic profiling with African-specific variant interpretation, ISO 20387-accredited biobanking for population genomics and longitudinal studies, and end-to-end GCP/GLP-compliant clinical trial central lab services covering patient screening, biosample acquisition, biomarker testing, and regulatory data packages. Technical infrastructure includes the first deployment in Sub-Saharan Africa of the QIAGEN NeuMoDx 96 molecular diagnostics platform, which received Ghana FDA approval for infectious disease, blood-borne virus, and reproductive health testing. The company is also building what it describes as Africa's most comprehensive African population genomic dataset, alongside an African-specific pharmacogenomic variant database covering key CYP genes and G6PD. Its proprietary ROBIN platform combines computer vision with structured bioinformatics for AI-assisted digital slide analysis and pathology interpretation.

The revenue model combines multiple streams: per-test and service fees for clinical diagnostics, one-time fees for genomic and pharmacogenetic tests, recurring-style fees for biobanking storage and management, and professional services revenue from pharmaceutical, CRO, and academic clinical trial sponsors. Go-to-market is predominantly direct B2B enterprise sales to pharma and research clients via the Horsham US office and the Accra facility, complemented by direct lab services to patients and providers through the Accra facility (phone, WhatsApp, email). Pricing is not publicly disclosed; all services are quote-based and determined by test panel, service type, and client requirements. Strategic partners include AstraZeneca (companion diagnostics for EGFR in lung cancer), QIAGEN (NeuMoDx 96 deployment), Microsoft (cloud and data infrastructure), Diatech Pharmacogenetics (PGx interpretation tools), NalaGenetics, the Henry Jackson Foundation, OMEGA Research Group Florida, and the Ghana College of Physicians and Surgeons (training and capacity-building under a five-year MOU signed in April 2026). The company has raised undisclosed rounds from Jaza Rift Ventures (2023), DeveloPPP Ventures (2024), and Mirepa Capital (2026).

Name

Revna Biosciences

Legal name

Revna Biosciences

Website

https://revnabio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Revna Biosciences operates Africa's first triple A2LA ISO-accredited precision medicine laboratory in Accra, Ghana, offering clinical diagnostics, genomic and pharmacogenetic testing, biobanking, and clinical trial central lab services to healthcare providers, researchers, and pharmaceutical sponsors across West Africa.

Ownership category

akta.pro rank

Product category

Precision Medicine and Clinical Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)

Keywords

• Clinical diagnostics services
• Genomic testing services
• Biobanking services
• Pharmacogenetics testing
• Precision medicine research

Headquarters

HQ city

Accra

HQ country

Ghana

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Diagnostics Services: ISO 15189-accredited medical laboratory testing for patient care and clinical research including haematology, clinical biochemistry, immunology, microbiology, serology, and advanced molecular diagnostics. Revenue generated through per-test and service fees for healthcare providers and patients.
2. Genomic and Genetic Testing: Comprehensive genomic and genetic testing services including whole genome sequencing, whole exome sequencing, targeted gene panels, EGFR testing, and pharmacogenomic profiling. Revenue from molecular testing services to patients, clinicians, and research institutions.
3. Biobanking Services: ISO 20387-accredited biorepository services for collection, processing, cryostorage, and distribution of biological specimens. Serving population genetics research, longitudinal clinical studies, and multi-site clinical trials.
4. Clinical Trials Central Lab Services: End-to-end central laboratory services for clinical trial sponsors operating in Africa including patient screening, biosample acquisition, biobanking, bioanalysis, biomarker testing, and regulatory data packages. Revenue from pharmaceutical, CRO, and academic sponsors.
5. Pharmacogenetics and Pharmacogenomics: Pharmacogenetic testing and pharmacogenomic profiling for African patients and research cohorts, including actionable PGx reports for clinicians and African-specific variant interpretation.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Revna Biosciences operates a triple A2LA ISO-accredited precision medicine laboratory in Accra, Ghana, delivering clinical diagnostics (haematology, biochemistry, immunology, microbiology, molecular diagnostics), genomic and genetic testing (WGS, WES, targeted panels, EGFR), pharmacogenetics, population genetics research, ISO-accredited biobanking, and GCP/GLP-compliant clinical trial central lab services. The ROBIN AI-assisted digital pathology platform augments diagnostic interpretation. Services are tailored for African populations and produce regulatory-grade data accepted by FDA, EMA, and WHO.

Product overview

Revna Biosciences operates as an integrated precision medicine platform delivering clinical diagnostics, genomic testing, biobanking, pharmacogenetics, population genetics research, and clinical trial support services from its Accra, Ghana facility. The platform is unified under triple A2LA ISO accreditation (ISO 15189, ISO 20387, ISO/IEC 17043) and augmented by the ROBIN AI-assisted digital pathology platform for computer vision capabilities. Services are designed for African populations and include clinical diagnostics, comprehensive genomic and genetic testing (WGS/WES/panels), pharmacogenetic profiling, population genomics, ISO-certified biobanking, and GCP/GLP-compliant clinical trial central lab services—all producing globally accepted, regulatory-grade data for FDA, EMA, and WHO submissions.

Differentiator

Problem solved

Functional benefit

Brands

• ROBIN: AI-assisted digital pathology platform supporting digital slide analysis and pathology interpretation.

Products and services

• ROBIN AI-Assisted Digital Pathology Platform AI-assisted digital pathology platform that processes visual inputs for digital slide analysis and pathology interpretation, enabling automated diagnostics and computer vision capabilities for laboratory medicine and pathologist decision support.
• Clinical Diagnostics Services ISO 15189-accredited medical laboratory testing for patient care and clinical research, covering haematology, clinical biochemistry, immunology, microbiology, serology, and advanced molecular diagnostics for patients and clinicians.
• Genomic and Genetic Testing Comprehensive genomic and genetic testing services including whole genome sequencing (WGS), whole exome sequencing (WES), targeted gene panels, carrier screening, and EGFR testing for patients, clinicians, and research institutions.
• Pharmacogenetics and Pharmacogenomics Pharmacogenetic testing and pharmacogenomic profiling for African patients, identifying how African-specific genetic variation affects drug metabolism, efficacy, and safety, with actionable PGx reports for clinicians.
• Population Genetics and Genomics Research Research-grade population genetics and genomic studies in African cohorts, generating African-specific genomic reference data, allele frequency databases, and population structure analysis for academic and institutional researchers.
• Biobanking and Sample Management ISO 20387-accredited biorepository for collection, processing, cryostorage, and distribution of African biospecimens, serving population genetics research, longitudinal clinical studies, and multi-site clinical trials.
• Clinical Trials Central Lab Services End-to-end GCP/GLP-compliant central laboratory services for clinical trial sponsors operating in Africa, including patient screening, biosample acquisition, biobanking, bioanalysis, biomarker testing, and regulatory data packages.
• Precision Medicine Services African-specific biomarker discovery and validation, oncology precision diagnostics, infectious disease genomics, and clinical implementation of precision medicine tools for African healthcare settings.

Quantifiable outcome

• No international sample shipping degradation
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, active and flagship.

• Ghana College of Physicians and SurgeonscoreStrategic or Co-development Partner · 1 April 2026Strategic MOU signed in April 2026 to establish collaborative training, research, and capacity-building initiatives. Includes structured fellowship training, joint research initiatives, supervised rotations, conferences, scientific publications, and grant opportunities. Provides Fellows exposure to ROBIN AI platform, molecular diagnostics, genomics, microbiology, digital pathology, and biobanking. Initial five-year term.
• NalaGeneticsactiveTechnology or IntegrationSingapore-based partnership for DNA tests tailored to Africans, enhancing disease detection and treatment for African populations through pharmacogenetic testing and genomic analysis.
• AstraZenecaflagshipStrategic or Co-development PartnerActive partnership for EGFR biomarker testing for lung cancer in Ghana, bringing companion diagnostic capabilities to West African oncology patients and generating EGFR mutation data in Ghanaian and West African cancer cohorts.
• MicrosoftcoreTechnology or IntegrationTechnology partnership providing cloud infrastructure and technology solutions supporting RevnaBio's laboratory operations, data management, and digital platform capabilities.
• QIAGENcoreTechnology or IntegrationPartnership for NeuMoDx 96 molecular diagnostics platform deployment - the first in Sub-Saharan Africa, approved by Ghana FDA for advanced molecular diagnostics for infectious disease, blood-borne viruses, and sexual and reproductive health.
• Henry Jackson FoundationcoreStrategic or Co-development PartnerPartnership with military medical research foundation supporting biomedical research initiatives and clinical research infrastructure development in Africa.
• OMEGA Research Group FloridacoreStrategic or Co-development PartnerResearch partnership for clinical and biomedical research collaboration, contributing to population genetics and pharmacogenomics research programs.
• Diatech PharmacogeneticscoreTechnology or IntegrationPartnership bringing state-of-the-art pharmacogenomic capabilities to West Africa. Powers African PGx research through African-specific variant databases and pharmacogenetic testing services for CYP genes, G6PD, and other pharmacogenes.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• 54gene: African genomics and molecular diagnostics company founded in Lagos, Nigeria, focused on building African genomic datasets and operating clinical research services. Most directly comparable peer on African precision medicine positioning and genomic data advantage.
• Helix: US-based clinical genomics laboratory operating CLIA/CAP-accredited next-generation sequencing and population genomics programs. Comparable as a clinical genomics lab with proprietary data assets and pharma/research partnerships, though without the African specialization.
• Color: US clinical genomics and population health laboratory offering genetic testing, pharmacogenomics, and clinical research services at scale. Comparable operating model (CLIA lab + population health + pharma partnerships) and technology-forward approach to genetic testing at scale.
• NalaGenetics: Singapore-based clinical genomics company providing DNA tests tailored to Asian and African populations with pharmacogenomic profiling capabilities. Direct peer as active partner of RevnaBio addressing under-served population genetics.

Regional players

• Inqaba Biotechnical Industries: South Africa-based genomics services and life sciences supplier offering Sanger sequencing, NGS, and oligonucleotide synthesis across Africa. Regional peer providing genomics infrastructure across Sub-Saharan Africa though with a less clinical-services focus.
• Cerba Lancet Africa: Pan-African clinical diagnostics network (joint venture between Cerba HealthCare and Lancet Laboratories) operating ISO-accredited pathology and clinical laboratories across multiple African countries. Regional peer operating comparable ISO-accredited clinical laboratory services in Africa.

Broad incumbents

• Eurofins Genomics: Global clinical diagnostics and genomics laboratory network operating ISO/IEC 17025-accredited facilities worldwide. Comparable as broad incumbent with overlapping capabilities in genomic services, biobanking, and clinical trial support, though broader portfolio without African specialization.
• Synlab: Europe's largest medical diagnostics services provider operating clinical laboratories with ISO 15189 accreditation across multiple countries. Broad incumbent with overlapping medical laboratory and clinical diagnostics capabilities.
• IQVIA Laboratories: Global central laboratory and bioanalytical services business of IQVIA supporting clinical trials at scale with biobanking, biomarker, and central lab capabilities. Comparable as clinical trial central lab provider though competing at much larger scale.

Emerging players

• Genomic Prediction: US-based clinical genomics laboratory offering embryo and population genetic screening with proprietary variant interpretation. Emerging player with comparable focus on advanced clinical genomics, though narrower therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• Xx.com/RevnaBio
• LinkedInlinkedin.com/company/revnabiosciences

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revna Biosciences